Premium
Low molecular weight heparin for the prevention of severe preeclampsia: where next?
Author(s) -
McLaughlin Kelsey,
Scholten Ralph R.,
Parker John D.,
Ferrazzi Enrico,
Kingdom John C. P.
Publication year - 2018
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.13483
Subject(s) - preeclampsia , low molecular weight heparin , medicine , heparin , clinical trial , intensive care medicine , bioinformatics , pregnancy , pharmacology , biology , genetics
Low molecular weight heparin has been extensively evaluated for the prevention of preeclampsia in high‐risk pregnant women; however, the results from these trials have been conflicting. This review discusses the potential mechanisms of action of low molecular weight heparin for the prevention of severe preeclampsia, how to optimize the selection of high‐risk women for participation in future trials, and the importance of trial standardization.